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Occasionally, both advanced small-cell lung cancers (SCLC) and
non-small-cell lung cancers (NSCLC) can cause carcinomatous
pericarditis. Malignant pericarditis is critically and inevitably
associated with pericardial effusion which, in turn, incites cardiac
tamponade (Press and Livingston, 1987). This is a life-threatening
situation especially in terminal cases because malignant cardiac
tamponade invariably results in acute cardiac failure. Therefore,
by controlling pericardial effusion, the quality of life of these
terminally ill patients may be improved.
Malignant pleuritis in patients having SCLC is effectively
controlled by systemic, multi-drug chemotherapy (Livingston
et al, 1982; Herrstedt et al, 1992). Accordingly, the most prudent
option for controlling primary and metastatic lesions in these
cases, or even for controlling malignant pericarditis, is a combina-
tion of systemic chemotherapy and effusion extraction to relieve
cardiac tamponade. For patients with NSCLC, however, a
systemic chemotherapeutic regimen generally has a relatively
brief and low response rate of 20–50% (Woods et al, 1990;
Souquet et al, 1993), making regional treatment of malignant peri-
carditis much more meaningful. In addition, since this condition
arises in terminally ill patients having NSCLC (Press and
Livingston, 1987), intensive therapy such as combination
chemotherapy often cannot be considered. The most commonly
applied treatment for malignant pericarditis in NSCLC patients
consists of simple drainage of the pericardial effusion (Shinkai et
al, 1982; Roth et al, 1989), although it is not without controversy
(Okamoto et al, 1993). The topical instillation of some kinds of
chemotherapeutic or sclerosing agents has at times been per-
formed in an attempt to achieve a better outcome (Smith et al,
1974; Shepherd et al, 1987; Celermajor et al, 1991; Vaitkus et al,
1994; Maher et al, 1996). Especially, Maher et al reported results
from a large-scale study of 93 patients with malignant pericarditis
and cardiac tamponade caused by a variety of malignant diseases
including 45 lung cancers. They employed the intrapericardial
administration of tetracycline hydrochloride or doxycyclin hydro-
chloride and suggested that pericardial sclerosis provided similar
survival with lower mortality and recurrence rates when compared
to the outcomes of drainage by video-assisted thoracoscopic
surgery or subxiphoid pericardial window creation with tube
drainage. Unfortunately, the fact that there has been no systematic
prospective investigation has prevented the confirmation of this
advantage, and any such alternative method must first be evaluated
for both its efficacy and safety. Only then can conclusions be
drawn from phase III studies in which the two methods are directly
compared. For designing phase III studies, alternative methods
including the topical instillation of cytotoxic agents need to be
investigated in either a pilot study or a phase II study.
This report describes the usefulness and pharmacokinetics data
of topically injected carboplatin for patients with NSCLC and
malignant cardiac tamponade.
PATIENTS AND METHODS
Eligibility criteria for selecting patients
Ten patients, having met all of the following conditions, were
enrolled in the study: 1. histologically and/or cytologically proven
NSCLC, 2. massive pericardial fluid proven to contain malignant
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tive symptoms and physical signs, electrocardiograms, chest
X-rays, echo cardiograph and CT scan images, 4. age from 16 to
80 years, 5. performance status (PS) from 1 to 4, 6. normal bone
marrow function with Hb ³ 9 g/dl, WBC ³ 3000/ml, Plt ³ 100
000/ml, tolerable liver function showing serum GOT and GPT
within two-fold the normal value, and normal renal function
showing serum creatinine not exceeding 1.5 mg/dl, 7. expected
survival period of more than four weeks if cardiac tamponade
could be controlled, 8. no chemotherapy, radiotherapy or surgery
at least one month prior to the treatment, and 9. written informed
consent. This study fully complies with institutional regulations.
Treatment method
After laying the patient down in a semi-Furler position and
applying local anaesthesia, a 5 French or 16 Gauge catheter was
percutaneously inserted into the pericardial cavity under echo-
cardiographic guidance. The effusion was completely drained
through the catheter, and the cavity was then washed several times
with heparinized saline. After infusing 300 mg of carboplatin and
100 mg of lidocaine dissolved in 50 ml of normal saline via the
catheter into the pericardial cavity, the catheter was then occluded
for 40 minutes. During this period the patients could opt for
supine, right-sided, left-sided and prone positions for 10 minutes
each. Upon reopening the catheter, any remaining effusion was
manually drained once a day until it reached less than 30 ml/day, at
which point the catheter was removed. In cases where the catheter
could not be removed within five days following the treatment,
carboplation was administered one more time.
Definition of effectiveness
Since terminally ill patients with advanced NSCLC are survival-
limited, the following criteria were used to evaluate the advantages
of this treatment.
Major response
No continuous drainage requirement, no pericardial effusion
recurrence and no signs of cardiac tamponade requiring further
treatment for at least 4 weeks and/or until expiration.
Moderate response
No continuous drainage requirement, no significant pericardial
effusion recurrence and no signs of cardiac tamponade requiring
further treatment for at least 4 weeks, but drainage reinstallation
being required beyond this period.
No response
Continuous drainage requirement or drainage reinstallation during
the first 4 weeks.
Pharmacokinetics study
Circulating venous blood and pericardial fluid samples were
collected in heparinized tubes at 0, 15, 30 minutes, and 1, 2, 4, 8,
16 and 32 hours after reopening the drainage catheter. All samples
were directly centrifuged at 3000 rpm for 20 minutes to isolate the
plasma. A 2 ml portion of each plasma gradient was then placed on
a Centrifree MPS-3 conical filter (Amicon Corp., Lexington,
Mass., USA) and centrifuged again at 3000 rpm for 20 minutes to
eliminate existing protein and protein-bound platinum. A prelimi-
nary study revealed that this filtered plasma was transparent and
contained less than 2% plasma protein (data not shown). The
filtered and unfiltered samples were stored at –70°C until measure-
ment. All samples were measured for platinum concentrations by
Flameless Atomic Absorption Spectroscopy using the same instru-
mentation and method as reported earlier (Pera and Harde, 1977).
By this analysis, the lowest detectable platinum concentration was
50 ng/ml.
Then, the measured platinum concentrations were fitted to a
two-compartment open model using a nonlinear regression
program based on a simplex algorithm. Justification for choosing
this particular model has been previously established (Patton et al,
1978).
RESULTS
Effectiveness for controlling malignant effusion
The characteristics of the 10 patients are summarized in Table 1.
All patients had adenocarcinoma and the median age of the 6 men
and 4 women was 54 years (range 44 to 72). Although nine
patients unquestionably had clinical stage IV disease at the time of
cardiac tamponade diagnosis, the remaining patient (case 2 in
Table 1), diagnosed with clinical stage IIIB or IV, refused to be
completely evaluated for clinical stage. PS of the 10 patients is
also shown in Table 1. Each patient deteriorated to a PS of 4
because of cardiac tamponade.
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Table 1 Patient characteristics and results
No. of administrations Duration of drainage Response Survivalc
Patient no. Agea Sex Cell type Clinical stage PS of carboplatin (days) (days)
1 44 Male Adb T4N3M1 4 1 6 Major 29
2 49 Male Ad T4N3Mx 4 2 13 Major 53
3 52 Male Ad T4N3M1 4 1 6 Major 79
4 51 Female Ad T4N3M1 4 1 4 Major 59
5 56 Male Ad T4N3M1 4 1 5 Major 38
6 58 Male Ad T4N3M1 4 2 11 Major 176
7 63 Male Ad T4N3M1 4 2 16 Major 100
8 57 Female Ad T4N3M1 4 2 8 Major 112
9 48 Female Ad T4N3M1 4 2 14 Moderate 158
10 72 Female Ad T4N3M1 4 2 31 No response 32
a Median age, 54 years; b adenocarcinoma of lung; c median survival time from the start of CBDCA intrapericardial administration, 69 days.The result of the intrapericardial administration of carboplatin
and successive draining of pericardial effusions was favourable.
Among the 10 cases, there were 8 major responders, one moderate
responder and one non-responder (Table 1). As for the 4 major
responders (cases 1, 3, 4 and 5) who required only one injection of
carboplatin, the drainage tubes were removed within 6 days after
treatment without the recurrence of pericardial effusion. The other
four major responders (cases 2, 6, 7 and 8) required a second injec-
tion of carboplatin to achieve a major response. Case 1 expired at
29 days after treatment because of tumour haemoptysis. Case 9
experienced a pericardial effusion recurrence 89 days after the first
carboplatin injection and, being judged as a moderate responder,
was subsequently treated again. This re-injection of carboplatin
was effective for another 67 days until her death. Case 10 required
continuous pericardial drainage of more than 30 ml for 31 days
after treatment or until her death, and was consequently judged as
a non-responder. The overall median survival time for these ten
patients was 69 days (ranging from 29 to 176 days).
Adverse effects
No significant adverse effects such as fever, infection, retrosternal
pain, new arrhythmia, or deterioration of laboratory data were
observed during this study. Although the effused pericardial fluid
was moderately viscous in most patients, the drainage tube only
rarely became blocked, and then the obstruction was easily flushed
out with heparinized saline.
All 10 patients died because of progressing cancer, but they
were without any clinical symptoms related to cardiac tamponade
at the time of their passing. Most importantly, no evidence of peri-
cardial constriction was ever observed.
Carboplatin pharmacokinetics in pericardial fluid and
circulating blood
Seven cases (cases 1, 2, 3, 5, 7, 9 and 10) gave carboplatin phar-
macokinetics data in pericardial fluid and four cases (cases 3, 5, 7
and 9) gave the data in circulating blood. The pharmacokinetics
parameters of platinum are given in Table 2 and the mean decay
curves for platinum in pericardial fluid and circulating plasma are
shown in Figures 1A and 1B, respectively.
Peak concentrations of platinum in pericardial fluid were
reached immediately following intrapericardial administration,
after which they declined (Fig. 1A). The area under the concentra-
tion–time curve (AUC) of total platinum in pericardial fluid was
462.8 ± 253.1 mg ´ h/ml and that of free platinum 385.1 ± 221.7
mg ´ h/ml (Fig. 1A and Table 2). Concentrations of total platinum
in pericardial fluid declined in a bi-exponential fashion with a and
b half-lives of 0.52 ± 0.06 and 9.93 ± 7.07 hours, respectively.
Concentrations of ultrafiltrable platinum, or free platinum, also
declined in a bi-exponential fashion with a and b half-lives of
0.46 ± 0.09 and 5.06 ± 2.23 hours, respectively. The percentage of
free platinum in pericardial fluid was more than 70% one hour
after reopening the catheter, then declining to 50% at 8 hours.
The total platinum and free platinum concentrations in plasma
declined in a bi-exponential fashion. Platinum concentrations in
circulating blood showed a peak at 15 min after beginning
drainage. The maximum concentration (Cmax) of serum total plat-
inum was 5.8 ± 4.8 mg/ml, or 0.8% of that in pericardial fluid.
AUC of total platinum in plasma fluid was 33.3 ± 14.0 mg ´ h/ml
and that of free platinum was 11.3 ± 4.1 mg ´ h/ml (Fig. 1B and
Table 2).
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Table 2 Pharmacokinetic parameters of platinum in pericardial fluid and
plasma
Cmax AUC t1/2a t1/2b
(mg/ml) (mg h/ml) (h) (h)
Pericardial fluid total platinum 715.8 462.8 0.52 9.93
± 241.9 ± 253.1 ± 0.06 ± 7.07
free platinum 643.0 385.1 0.46 5.06
± 241.6 ± 221.7 ± 0.09 ± 2.23
Plasma total platinum 5.8 33.3 1.92 20.89
± 4.8 ± 14.0 ± 0.60 ± 9.97
free platinum 3.8 11.3 1.86 2.56
± 1.5 ± 4.1 ± 0.70 ± 0.20
Cmax: Maximum concentration; AUC: area under the concentration-time
curve; T1/2a: a-phase half-life; T1/2b: b-phase half-life.
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Figure 1 Platinum concentration in intrapericardial space (A) and in
circulating plasma (B), in patients treated with intrapericardial administration
of carboplatin. Fluid samples were collected at 1, 15, 30 minutes and 1, 2, 4,
8, 16, 32 hours after reopening the occluded drainage catheter. The data
consists of 7 patients in A and 4 patients in B. Each point represents the
mean and each bar represents the standard deviation of the total platinum
(solid line) and free platinum (dotted line)DISCUSSION
The basic standard therapeutic method for relieving and control-
ling malignant pericardial effusion that accompanies NSCLC is a
percutaneous pericardiocentesis followed by drainage through an
in-place catheter (Shinkai et al, 1982; Roth et al, 1989). For malig-
nant pericarditis coexisting with various kinds of malignancies,
including but not limited to lung cancer, an additional topical
instillation of sclerosing or cytotoxic agents is reportedly effective
(see references in Table 3). Any retrospective study, however, has
failed to demonstrate how such sclerosing agents and cytotoxic
agents are superior to standard pericardiocentesis and drainage
(Okamoto et al, 1993). This means that a standard treatment for
malignant pericardial effusion in patients with NSCLC has not
been clearly established until now.
In a first attempt to address this issue, the effectiveness and reli-
ability of percutaneous pericardiocentesis combined with the
draining of effused pericardial fluid and topically administering
carboplatin were prospectively evaluated in this study. Carboplatin
was chosen for this purpose because it is one of the most effective
chemotherapeutic agents for NSCLC, as well as cisplatin, in a
variety of clinical situations (Lokich and Anderson, 1988; Go and
Adjei 1999). Only a few case reports have shown the successful
use of the intrapericardial administration of carboplatin for
controlling malignant pericarditis (Gotoh et al, 1991; Takahashi et
al, 1994). Our present results with carboplatin were satisfactory in
terms of both its potency and safety. Eight and one of the ten
patients showed a major and a moderate response, respectively,
resulting in a 90% success rate according to the previously
mentioned criteria. No trace of toxicity was observed in any of the
ten patients. With respect of effectiveness, these results with
carboplatin are comparable to the above-mentioned studies (Table
3) utilizing tetracycline, doxycycline, bleomycin or cisplatin. In
fact, as is the case with bleomycin, the use of carboplatin is highly
preferable when considering the harmful side effects typically
associated with tetracycline, doxycycline and cisplatin.
The pharmacokinetics data for pericardial fluid and circulating
blood clearly appear to support these clinical outcomes. That is, as
much as 600 mg/ml of free platinum was retained for as long 
as 40 minutes during which the catheter was occluded. More
impressively, more than 60 mg/ml of that amount was still retained
one hour after reopening the catheter (Fig. 1A). Such high concen-
trations of free platinum existing for 1.5 hours are theoretically
enough to kill all cancer cells when considering another in vitro
study (Takashashi et al, 1987).
The pharmacokinetics data obtained in a phase I study (van
Echo et al, 1984) were comparable to both the plasma Cmax and
AUC presented here. In patients with normal renal function, the
plasma Cmax of this method corresponded to the Cmax of 5.98 mg/ml
for which 77 mg/m2 of carboplatin had been intravenously
injected. Similarly, the plasma AUC of this method was
comparable to the AUC of 22.6 mg ´ h/ml for which 77 mg/m2 of
carboplatin had been intravenously injected (Table 2).
Such low doses of carboplatin caused few systemic adverse
effects in phase I studies (Calvert et al, 1982; Curt et al, 1983) and,
to date, there have been no systemic complications in our pro-
cedure. Another group (Lerner-Tung et al, 1997) administered 
5-fluorouracil followed by cisplatin into the pericardial space of a
patient with metastatic breast adenocarcinoma, and the pharmaco-
kinetics of this drug in the pericardial space and circulating plasma
were investigated. The results revealed a high concentration within
the pericardial sac, with a greatly increased half-life over that of
systemic delivery, with little systemic toxicity, resembling our
results. Systemically delivering chemotherapeutic agents may be
advantageous for controlling disseminated lesions only under
particular conditions. However, patients suffering from NSCLC
and malignant pericarditis are most likely too advanced in terms of
disease. As is commonly the case, systemic delivery of these
agents is no longer effective for enhancing the quality of life or for
prolonging the survival time of such patients. Therefore, the phar-
macokinetics data presented here validates the suitability of our
method when applied to the clinical situation of our 10 patients.
To treat patients with malignant pericardial effusion and
NSCLC, the present study can not establish whether topically
administrating carboplatin followed by drainage is superior to
minimal pericardiocentesis followed by drainage, because no
prospective comparative study has been conducted. Discussions
on the clinical relevance of intrapericardial administration of other
sclerosing and cytotoxic agents have also been equivocal. A
conclusion could be plainly drawn from directly comparing these
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Table 3 Summary of published studies on typical administration of sclerosing or cytotoxic agents for treating malignant pericardial effusion
Agent Investigatora Year Efficiencyb,c Adverse effects
Tetracycline hydrochloride Davis et al 1984 30/33 (91%) None
Shepherd et al 1987 43/58 (74%) Pain, fever, arrhythmia
Celermajor et al 1991 19/26 (73%) Pain
Doxycycline hyclate Kitamura et al 1981 7/7 (100%) Pain
Doxycycline hydrochloride Liu et al 1996 6/9 (67%) Pain, fever, arrhythmia
Tetracycline hydrochloride Maher et al 1996 68/85 (79%) Pain, fever, arrhythmia
or
doxycycline hydrochloride
Bleomycin sulfate Yano et al 1994 5/7 (71%) None
Liu et al 1996 9/11 (82%) Fever, arrhythmia
Mitomycin C Lee et al 1994 14/20 (70%) None
Cisplatin Fiorentino et al 1988 3/6 (50%) Nausea
Tomkowski et al 1994 9/9 (100%) Nausea, arrhythmia
Tomkowski et al 1997 15/16 (93%) Nausea, arrhythmia
Thiotepa Colleoni et al 1998 19/23 (83%) Thrombocytopenia, leukopenia
32P-colloid Dempke et al 1999 34/36 (95%) Tachycardia
a All reports are cited in the References; b No. of Pt. showing effectiveness/No. of total Pt; c patients consist of lung cancer and other malignant diseases.862 T Moriya et al
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methods to the standard approach. Phase III studies are warranted
to compare minimal pericardiocentesis followed by drainage to
intrapericardial administration of a sclerosing or cytotoxic agent
combined with the minimal approach for controlling malignant
pericardial effusion with NSCLC. Carboplatin is one of the most
promising candidates to be included in such studies.
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